Vyome Holdings, Inc.
$2.35
▼
-0.93%
2026-04-21 07:17:01
www.vyometx.com
NCM: HIND
Explore Vyome Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$16.49 M
Current Price
$2.35
52W High / Low
$56.36 / $1.75
Stock P/E
—
Book Value
$0.41
Dividend Yield
—
ROCE
-73.02%
ROE
1053.07%
Face Value
—
EPS
$-4.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
—
Debt / Equity
0.83
Current Ratio
1.99
Quick Ratio
1.99
Forward P/E
—
Price / Sales
48.08
Enterprise Value
$11.74 M
EV / EBITDA
-4.29
EV / Revenue
36.72
Rating
None
Target Price
$15
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Edesa Biotech, Inc. | $6.75 | — | $49.5 M | — | -57.24% | -96.39% | $9.37 / $0.72 | $0.56 |
| 2. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 3. | Aura Biosciences, Inc. | $7.05 | — | $467.66 M | — | -74.67% | -73.52% | $7.48 / $4.34 | $2.15 |
| 4. | Cellectar Biosciences, Inc. | $2.95 | — | $12.21 M | — | -224.66% | -1.7% | $20.7 / $2.43 | $1.89 |
| 5. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 6. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 7. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 0.04 M | 0.03 M | 0.06 M | 0.08 M |
| Operating Profit | -1.36 M | -0.87 M | -0.26 M | -0.28 M |
| Net Profit | -1.06 M | -8.6 M | -0.31 M | -0.55 M |
| EPS in Rs | -0.15 | -1.22 | -0.04 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.32 M | 0.26 M | 0.42 M | 0.38 M |
| Operating Profit | -2.75 M | -1.01 M | -0.77 M | -1.1 M |
| Net Profit | -10.26 M | -1.45 M | -0.72 M | -1.26 M |
| EPS in Rs | -1.46 | -0.21 | -0.1 | -0.18 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.5 M | 1.38 M | 1.42 M | 1.79 M |
| Total Liabilities | 2.74 M | 5.77 M | 7.51 M | 7.15 M |
| Equity | 2.44 M | -4.39 M | -6.09 M | -5.37 M |
| Current Assets | 5.44 M | 0.3 M | 0.17 M | 0.53 M |
| Current Liabilities | 2.74 M | 5.74 M | 6.48 M | 4.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.75 M | -0.61 M | -0.56 M | -0.36 M |
| Investing CF | 0 M | 0 M | 0 M | 0 M |
| Financing CF | 8.65 M | 0.7 M | 0.12 M | 0.75 M |
| Free CF | -3.75 M | -0.61 M | -0.56 M | -0.36 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 24.43% | -38.23% | 8.64% | — |
| Earnings Growth % | -608.97% | -101.06% | 42.65% | — |
| Profit Margin % | -3209.75% | -563.34% | -173.08% | -327.87% |
| Operating Margin % | -859.22% | -391.66% | -184.57% | -288.4% |
| Gross Margin % | 68.43% | 75.88% | 67.93% | 38.16% |
| EBITDA Margin % | -3227.6% | -476.41% | -128.4% | -280.56% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-15 | 1:0.25 |
| 2025-05-09 | 1:0.04 |
| 2024-09-23 | 1:0.0172414 |
| 2022-12-23 | 1:0.02 |